Faderl S - Search Results

1

The JAK-STAT pathway: a therapeutic target in hematological malignancies.

Ferrajoli A, Faderl S, Ravandi F, Estrov Z. Ferrajoli A, et al. Among authors: faderl s. Curr Cancer Drug Targets. 2006 Dec;6(8):671-9. doi: 10.2174/156800906779010227. Curr Cancer Drug Targets. 2006. PMID: 17168672 Review.

2

Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.

Ravandi F, Kantarjian HM, Talpaz M, O'Brien S, Faderl S, Giles FJ, Thomas D, Cortes J, Andreeff M, Estrov Z, Rios MB, Albitar M. Ravandi F, et al. Among authors: faderl s. Cancer. 2001 Jun 1;91(11):1964-72. doi: 10.1002/1097-0142(20010601)91:11<1964::aid-cncr1221>3.0.co;2-b. Cancer. 2001. PMID: 11391574

3

The clinical significance of caspase regulation in acute leukemia.

Faderl S, Estrov Z. Faderl S, et al. Leuk Lymphoma. 2001 Feb;40(5-6):471-81. doi: 10.3109/10428190109097646. Leuk Lymphoma. 2001. PMID: 11426520

4

Residual disease in acute lymphoblastic leukemia of childhood: methods of detection and clinical relevance.

Faderl S, Estrov Z. Faderl S, et al. Cytokines Cell Mol Ther. 1998 Jun;4(2):73-85. Cytokines Cell Mol Ther. 1998. PMID: 9681246 Review.

5

The clinical significance of detection of residual disease in childhood ALL.

Faderl S, Estrov Z. Faderl S, et al. Crit Rev Oncol Hematol. 1998 Jun;28(1):31-55. doi: 10.1016/s1040-8428(98)00008-0. Crit Rev Oncol Hematol. 1998. PMID: 9715769 Review. No abstract available.

6

Chronic myelogenous leukemia: biology and therapy.

Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Faderl S, et al. Ann Intern Med. 1999 Aug 3;131(3):207-19. doi: 10.7326/0003-4819-131-3-199908030-00008. Ann Intern Med. 1999. PMID: 10428738 Review.

7

Minimal residual disease in hematologic disorders.

Faderl S, Kurzrock R, Estrov Z. Faderl S, et al. Arch Pathol Lab Med. 1999 Nov;123(11):1030-4. doi: 10.5858/1999-123-1030-MRDIHD. Arch Pathol Lab Med. 1999. PMID: 10539902 Free article. Review.

8

The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia.

Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A, Kornblau SM, Cortes J, Thomas DA, Pierce S, Keating MJ, Estrov Z, Albitar M. Faderl S, et al. Cancer. 2000 Nov 1;89(9):1976-82. doi: 10.1002/1097-0142(20001101)89:9<1976::aid-cncr14>3.3.co;2-e. Cancer. 2000. PMID: 11064355

9

Clinical significance of minimal residual disease in leukemia.

Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Faderl S, et al. Int J Oncol. 2000 Dec;17(6):1277-87. doi: 10.3892/ijo.17.6.1277. Int J Oncol. 2000. PMID: 11078816 Review.

10

Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy.

Faderl S, Ferrajoli A, Frankfurt O, Pettitt A. Faderl S, et al. Leukemia. 2009 Mar;23(3):457-66. doi: 10.1038/leu.2008.322. Epub 2008 Nov 6. Leukemia. 2009. PMID: 18987653 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

386 results

Search Page